These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16455819)

  • 1. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen.
    Glaros S; Atanaskova N; Zhao C; Skafar DF; Reddy KB
    Mol Endocrinol; 2006 May; 20(5):996-1008. PubMed ID: 16455819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Fan P; Wang J; Santen RJ; Yue W
    Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.
    Wang LH; Yang XY; Zhang X; An P; Kim HJ; Huang J; Clarke R; Osborne CK; Inman JK; Appella E; Farrar WL
    Cancer Cell; 2006 Dec; 10(6):487-99. PubMed ID: 17157789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):511S-5S. PubMed ID: 12538508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
    Yang Z; Barnes CJ; Kumar R
    Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
    Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
    Pancholi S; Lykkesfeldt AE; Hilmi C; Banerjee S; Leary A; Drury S; Johnston S; Dowsett M; Martin LA
    Endocr Relat Cancer; 2008 Dec; 15(4):985-1002. PubMed ID: 18824559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentagalloylglucose inhibits estrogen receptor alpha by lysosome-dependent depletion and modulates ErbB/PI3K/Akt pathway in human breast cancer MCF-7 cells.
    Hua KT; Way TD; Lin JK
    Mol Carcinog; 2006 Aug; 45(8):551-60. PubMed ID: 16637063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
    Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
    Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
    Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
    Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
    Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
    Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
    Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
    J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha.
    Weitsman GE; Weebadda W; Ung K; Murphy LC
    Breast Cancer Res Treat; 2009 Nov; 118(2):269-79. PubMed ID: 18941890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.